Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate
Kailera Therapeutics (NASDAQ:KLRA) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.74) by 47.3 percent.
Read original at benzingaStocks · News reference
Kailera Therapeutics Announces Topline Data From Two Additional Phase 3 Clinical Trials Of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535 Conducted By Hengrui Pharma In China
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 7, 2026, 11:05 AM
- Checked
- Jul 7, 2026, 11:10 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Kailera Therapeutics, Inc. (KLRA)
Filed: 2026-08-12 AccNo: 0001193125-26-346919 Size: 411 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarWhy Is Kailera Therapeutics Stock Falling Tuesday?
Kailera Therapeutics oral GLP-1 meets Phase 3 targets for obesity and diabetes. KLRA stock falls 9% on reported GI side effects.
Read original at benzinga